Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Global X Lithium & Battery Tech ETF (LIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Global X Lithium & Battery Tech ETF — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.45 (market cap $5.07B), while Global X Lithium & Battery Tech ETF trades at $75. The key difference: ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Global X Lithium & Battery Tech ETF nearer its low. Which is the better fit depends on your goals.
| ACAD | LIT | |
|---|---|---|
Market Cap | $5.07B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $29.41 | $91.62 |
52-Week Low | $20.06 | $44.96 |
Enterprise Value | $4.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
LIT trades at $74.01, up 2.21% today, with bullish technical signals from moving averages but caution from oscillators. The stock has doubled over the past year, driven by strong momentum in electric vehicles, energy storage, and semiconductors. Recent news highlights global EV sales growth and China's ambitious 30% fleet target by 2030, supporting the lithium and battery technology theme.
Outlook remains positive given structural EV adoption trends, though overbought RSI levels suggest near-term consolidation risk. Key risks include Chinese export controls, regulatory changes, and competitive pressures. Analyst sentiment is constructive with buy ratings emphasizing long-term growth catalysts in clean energy transition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Global X Lithium & Battery Tech ETF
LIT invests in the full lithium cycle, from mining and refining to battery production and EV manufacturing. It tracks the Solactive Global Lithium Index, with top holdings including Rio Tinto, Albemarle, and Tesla, as well as major battery makers like Samsung SDI.
Read more on LIT →
